IL15 and neoplasm: In addition to IL-12 and IL-18, CAR T cells engineered to secrete IL-7, IL-15, and IL-21 (covered in more detail in the next section), although primarily intended to enhance the persistence and activity of the CAR T cells themselves, will also stimulate anti-tumour responses in bystander cells.